hemangioblast program (Astellas/CHA Bio & Diostech)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namehemangioblast program (Astellas/CHA Bio & Diostech)
Drug Alias Namehemangioblast program (Ocata/CHA Bio & Diostech)hemangioblast program (ACT)nuclear transfer-derived cell therapy (Advanced Cell Technology)hemangioblast program (Advanced Cell Technology/CHA Bio & Diostech)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Embryonic stem cells therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstellas Institute For Regenerative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCHA Bio & Diostech Co LtdAstellas Institute For Regenerative Medicine
Active IndicationsN/A
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A